Structural alterations of the central nervous system are demonstrated in people with diabetes. We aimed to characterise areas of global and anatomical grey matter volumes using T1-weighted magnetic resonance (MR) brain imaging (3-T MR imaging machine) in participants from the UK Biobank dataset. Participants with diabetes (DM) (n=569) and people without diabetes (CON) (n=20,801) were analysed. The mean age of DM diagnosis was 49.5±15 years. Baseline demographic and anthropometric data are as follows: DM group included more men (DM: 65% vs. CON: 47%) but were of a similar age (DM: 57.6±7.1 vs. CON: 55±7.5 years). BMI (DM: 29.6±5.2 vs. CON: 26.5±4.2 kgm2; p<0.0001) and systolic blood pressure (DM: 141±17 vs. CON: 137±19mmHg; p<0.0001) were higher in DM compared to CON with no difference in diastolic blood pressure (DM: 82±10 vs. CON: 81±10mmHg; p=NS). The majority of participants in both groups were right-handed (DM: 88.9%, CON: 89.1%) with a minority reporting ambidexterity (DM: 2.1%, CON: 1.5%). When comparing grey matter volume of DM vs. CON: peripheral cortical grey matter (corrected for head size) (599002±41503mm3 vs. 621942±40421mm3; p<0.0001), superior frontal gyrus (left: 10715±1695mm3 vs. 11056±1766mm3; p=0.001; right: 9279±1513mm3 vs. 9608±1612mm3; p<0.0001), left middle frontal gyrus (9894±1721mm3 vs. 10082±1786mm3; p=0.035), right anterior division of the supramarginal gyrus (3061±598mm3 vs. 3143±614mm3; p=0.001), right posterior supramarginal gyrus (5337±1052mm3 vs. 5476±1035mm3; p=0.002), paracingulate gyrus (left: 5558±866mm3 vs. 5749±856mm3; p=0.0006; right: 5456±845mm3 vs. 5700±852mm3; p<0.0001), precentral gyrus (left: 13712±1717mm3 vs. 14065±1748mm3; p=0.04; right: 13294±1652 vs. 13711±1731 p<0.0001) and left postcentral gyrus (10905±1481mm3 vs. 11313±1492mm3; p=0.0008) were all lower in DM compared to CON. People with diabetes have a significant reduction in global grey matter volume in distinct brain regions as previously described in the literature. Disclosure J. Burgess: None. S. S. Keller: None. I. N. Petropoulos: None. D. Selvarajah: None. S. Tesfaye: Advisory Panel; Self; Angellini, Bayer AG, Eva Pharma, Wörwag Pharma, Speaker's Bureau; Self; Abbott, AstraZeneca, Grunenthal Group, MSD Corporation, Novo Nordisk, Pfizer Inc. U. Alam: None.